Tal effector nuclease pair and use thereof

HK40137408APending Publication Date: 2026-09-11八幡 直樹 +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125144
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-25
Filing Date
2026-06-23
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a technique capable of cleaving one of a mutant mtDNA and a wild-type mtDNA more specifically. The TAL effector nuclease pair comprises a first TAL effector nuclease monomer and a second TAL effector nuclease monomer which have a target sequence interval of 12-20 bases, and each of the first TAL effector nuclease monomer and the second TAL effector nuclease monomer comprises a DNA binding domain which comprises RVD and binds to DNAs of 8-15 bases, and a DNA cleavage domain of FokI endonuclease; the RVDs include a first RVD that recognizes a base at a mitochondrial disease-inducing mutation site, and a second RVD that recognizes a base other than the mitochondrial disease-inducing mutation site, the first RVD being at least one of an NM that recognizes adenine, a WK that recognizes guanine, and an LK that recognizes guanine, the second RVD recognizing adenine by NI and guanine by NN.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480051034.5 (22) Application Date 2024.12.19 (30) Priority Data 2023-217626 2023.12.25 JP (85) PCT International Application Entering National Phase Date 2026.02.03 (86) PCT International Application Application Data PCT / JP2024 / 045076 2024.12.19 (87) PCT International Application Publication Data WO2025 / 142752 JA 2025.07.03 (71) Applicant Naoki Yawata Address Japan Applicant Ryuji Hata (72) Inventor Naoki Yawata Hata (74) Patent Agency Beijing J&J Intellectual Property Agency Co., Ltd. 11227 Patent Attorney Wang Yang (51) Int.Cl. C12N 15 / 09 (2006.01) A61K 48 / 00 (2006.01) A61K 38 / 46 (2006.01) A61P 43 / 00 (2006.01) C12N 9 / 16 (2006.01) C12N 15 / 55 (2006.01) C12N 15 / 63 (2006.01) (54) Invention Title TAL Effector Nuclease Pair and Its Application (57) Abstract This invention provides a technique that can more specifically cleave one of mutant mtDNA and wild-type mtDNA. The TAL effector nuclease pairs contain a first TAL effector nuclease monomer and a second TAL effector nuclease monomer with a target sequence interval of 12-20 bases. They each have: a DNA-binding domain containing an RVD that binds to DNA of 8-15 bases, and a DNA-cutting domain of the FokI endonuclease. The RVD contains a first RVD that recognizes a mitochondrial disease-induced mutation site and a second RVD that recognizes bases other than the mitochondrial disease-induced mutation site. The first RVD is at least one of NM (adenine), WK (guanine), and LK (guanine). The second RVD recognizes adenine by NI and guanine by NN.Claims (2 pages), Description (14 pages), Sequence Listing (electronic publication), Drawings (17 pages) CN 121666451 A 2026.03.13 CN 1 21 66 64 51 A 1. A TAL effector nuclease pair, comprising a first TAL effector nuclease monomer and a second TAL effector nuclease monomer, wherein the target sequence of the first TAL effector nuclease monomer is spaced 12-20 bases from the target sequence of the second TAL effector nuclease monomer; the first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have: a DNA-binding domain comprising an RVD that binds to DNA of 8-15 bases, and a DNA-cutting domain of a FokI nuclease; wherein the RVD comprises: a first RVD that recognizes a base that induces a mitochondrial disease mutation site, and a second RVD that recognizes a base other than the mitochondrial disease mutation site; wherein the first RVD is at least one of NM recognizing adenine, WK recognizing guanine, and LK recognizing guanine. The second RVD recognizes adenine by NI and guanine by NN. 2. The TAL effector nuclease pair according to claim 1, wherein the DNA cleavage domains of the FokI endonuclease in the first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have distinct amino acid sequences, forming a heterodimer. 3. The TAL effector nuclease pair according to claim 1, which binds to mutant mitochondrial DNA. 4. The TAL effector nuclease pair according to claim 1, which binds to wild-type mitochondrial DNA. 5. The TAL effector nuclease pair according to claim 1, wherein the mitochondrial disease-induced mutation is the A3243G mutation. 6. The TAL effector nuclease pair according to claim 5, wherein the RVD in the first TAL effector nuclease monomer is any one of NN-NN-HD-NI-NN-WK-NN-HD-HD-HD-NN, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-NN, and NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN. 7. The TAL effector nuclease pair according to claim 5, wherein the RVD in the second TAL effector nuclease monomer is any one of NI-NI-NI-NN-NG-NG-NG-NG-NG-NI-NI-NN-NG, NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN, and NN-NG-NI-NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG.8. The TAL effector nuclease pair according to claim 5, wherein the first TAL effector nuclease monomer is any one of the following amino acid sequences: the amino acid sequence shown in any one of Serial Numbers 1 to 3, an amino acid sequence having more than 90% homology with the amino acid sequence shown in any one of Serial Numbers 1 to 3, and an amino acid sequence in which one or more amino acid residues are missing, substituted, or added in the amino acid sequence shown in any one of Serial Numbers 1 to 3; and the second TAL effector nuclease monomer is any one of the following amino acid sequences: the amino acid sequence shown in any one of Serial Numbers 4, 19, and 20, an amino acid sequence having more than 90% homology with the amino acid sequence shown in any one of Serial Numbers 4, 19, and 20, and an amino acid sequence in which one or more amino acids are missing, substituted, or added in the amino acid sequence shown in any one of Serial Numbers 4, 19, and 20. Claims 1 / 2 Page 2 CN 121666451 A 9. A nucleic acid composition comprising a first nucleic acid encoding a first TAL effector nuclease monomer and a second nucleic acid encoding a second TAL effector nuclease monomer, wherein the target sequence of the first TAL effector nuclease monomer is spaced 12-20 bases from the target sequence of the second TAL effector nuclease monomer; the first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have: a DNA-binding domain comprising an RVD and binding to DNA of 8-15 bases, and a DNA-cutting domain of a FokI endonuclease; wherein the RVD comprises: a first RVD recognizing a base that induces a mitochondrial disease mutation site, and a second RVD recognizing a base other than the mitochondrial disease mutation site; the first RVD is at least one of NM recognizing adenine, WK recognizing guanine, and LK recognizing guanine, and the second RVD recognizes adenine by NI and guanine by NN. 10. A vector comprising the nucleic acid composition of claim 9. 11. A pharmaceutical composition comprising any one of the TAL effector nuclease pairs according to claims 1 to 8, the nucleic acid composition according to claim 9, or the carrier according to claim 10. Claims 2 / 2 pages 3 CN 121666451 A TAL effector nuclease pairs and their application technical field

[0001] This disclosure relates to TAL effector nuclease pairs. This application is based on Japanese Patent Application No. 2023-217626, filed on December 25, 2023, the contents of which are incorporated herein by reference. Background Art

[0002] It is known that some mitochondrial diseases caused by decreased mitochondrial function are caused by mutations in mitochondrial DNA (mtDNA) present in mitochondria. There are hundreds to thousands of copies of mtDNA in a cell.It is believed that in most cases, mutant mtDNA is mixed with normal wild-type mtDNA, and when the proportion of mutant mtDNA reaches a certain level, it will cause functional disorders. It is known that in the state of coexistence of mutant mtDNA and wild-type mtDNA (heterogeneity), if a double-strand break is introduced into one of the mtDNA, the broken mtDNA will disappear, and the ratio of mutant mtDNA to wild-type mtDNA can be changed. Genome editing technology containing transcription activator-like effector nuclease (TALEN) can introduce double-strand breaks into DNA with specificity. Therefore, the ratio of mutant mtDNA to wild-type mtDNA can be changed by designing TALEN that specifically cuts mutant mtDNA or wild-type mtDNA (e.g., Patent Document 1).

[0003] Prior Art Documents

[0004] Patent Documents

[0005] Patent Document 1: Japanese Patent Application Publication No. 2018-139580 Summary of the Invention

[0006] The symptoms of mitochondrial diseases caused by mtDNA mutations are complex, and there is currently no cure. Techniques that alter the mutation ratio of mtDNA can be used to reproduce symptoms and are expected to be used to elucidate the cause of the disease and develop treatments. In addition, if the proportion of mutated mtDNA can be reduced, it may be used as a fundamental treatment targeting the cause of the disease. Therefore, a technique that can more specifically cleave either mutated mtDNA or wild-type mtDNA has been sought.

[0007] This disclosure can be implemented in the following ways.

[0008] (1) According to one aspect of this disclosure, a TAL effector nuclease pair can be provided. This TAL effector nuclease pair comprises a first TAL effector nuclease monomer and a second TAL effector nuclease monomer. The target sequence of the first TAL effector nuclease monomer is spaced 12-20 bases from the target sequence of the second TAL effector nuclease monomer. Both the first and second TAL effector nuclease monomers have a DNA-binding domain containing an RVD that binds to DNA of 8-15 bases, and a DNA-cutting domain of a FokI endonuclease. The RVD comprises a first RVD that recognizes a mitochondrial disease-induced mutation site, and a second RVD that recognizes bases other than the mitochondrial disease-induced mutation site. The first RVD is at least one of NM (adenine), WK (guanine), and LK (guanine). The second RVD recognizes adenine by NI and guanine by NN. This TAL effector nuclease pair can more specifically cleave either mutant mtDNA or wild-type mtDNA.

[0009] (2) According to the TAL effector nuclease pair described in (1) above, wherein the DNA cleavage domains of the FokI endonuclease in the first TAL effector nuclease monomer and the second TAL effector nuclease monomer respectively have different amino acid sequences and form heterodimers. According to the TAL effector nuclease pair of this manner, since the FokI endonuclease forms heterodimers, it can more specifically cleave one of the mutant mtDNA and wild-type mtDNA as described on page 1 / 14 of the specification, CN 121666451 A.

[0010] (3) According to the TAL effector nuclease pair described in (1) or (2) above, it can bind to mutant mitochondrial DNA. According to the TAL effector nuclease pair of this manner, it can specifically cleave mutant mtDNA.

[0011] (4) According to the TAL effector nuclease pair described in (1) or (2) above, it can bind to wild-type mitochondrial DNA. According to the TAL effector nuclease pair of this method, wild-type mtDNA can be specifically cleaved.

[0012] (5) According to any one of (1) to (4) above, wherein the mitochondrial disease-induced mutation can be the A3243G mutation. According to the TAL effector nuclease pair of this method, one of the mutant mtDNA associated with the A3243G mutation and wild-type mtDNA can be specifically cleaved.

[0013] (6) According to the TAL effector nuclease pair of (5) above, wherein the RVD in the first TAL effector nuclease monomer can be any one of NN-NN-HD-NI-NN-WK-NN-HD-HD-HD-NN, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-NN, and NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN. According to this method of TAL effector nuclease pair, one of the mutant mtDNA and wild-type mtDNA associated with the A3243G mutation can be cleaved more specifically.

[0014] (7) According to the TAL effector nuclease pair described in (5) or (6) above, wherein the RVD in the second TAL effector nuclease monomer can be any one of NI-NI-NI-NN-NG-NG-NG-NG-NG-NI-NI-NN-NG, NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN, and NN-NG-NI-NI-NI-NN-NG-NG-NG-NG-NG-NI-NI-NN-NG. According to this method of TAL effector nuclease pair, one of the mutant mtDNA and wild-type mtDNA associated with the A3243G mutation can be cleaved more specifically.

[0015] (8) The TAL effector nuclease pair according to (5) to (7) above, wherein the first TAL effector nuclease monomer can be any of the amino acid sequences shown in any one of sequence numbers 1 to 3, an amino acid sequence having more than 90% homology with the amino acid sequences shown in any one of sequence numbers 1 to 3, or an amino acid sequence in which one or more amino acid residues are missing, replaced, or added in the amino acid sequences shown in any one of sequence numbers 1 to 3, and the second TAL effector nuclease monomer can be any of the amino acid sequences shown in any one of sequence numbers 4, 19, and 20, an amino acid sequence having more than 90% homology with the amino acid sequences shown in any one of sequence numbers 4, 19, and 20, or an amino acid sequence in which one or more amino acids are missing, replaced, or added in the amino acid sequences shown in any one of sequence numbers 4, 19, and 20. According to this method, the TAL effector nuclease pair can more specifically cleave one of the mutant mtDNA and wild-type mtDNA associated with the A3243G mutation.

[0016] (9) According to another aspect of the present disclosure, a nucleic acid composition may be provided. This nucleic acid composition comprises a first nucleic acid encoding a first TAL effector nuclease monomer and a second nucleic acid encoding a second TAL effector nuclease monomer, wherein the target sequence of the first TAL effector nuclease monomer is spaced 12-20 bases from the target sequence of the second TAL effector nuclease monomer. Both the first and second TAL effector nuclease monomers have: a DNA-binding domain containing an RVD that binds to DNA of 8-15 bases, and a DNA-cleaving domain of a FokI endonuclease. The RVD comprises: a first RVD recognizing a mitochondrial disease-induced mutation site, and a second RVD recognizing bases other than the mitochondrial disease-induced mutation site. The first RVD is at least one of NM recognizing adenine, WK recognizing guanine, and LK recognizing guanine. The second RVD recognizes adenine by NI and guanine by NN. According to this nucleic acid composition, a TAL effector nuclease pair capable of more specifically cleaving one of mutant mtDNA and wild-type mtDNA can be expressed.

[0017] (10) According to another aspect of the present disclosure, a vector containing the nucleic acid composition described in (9) above can be provided. The vector according to this aspect can express a nuclease pair capable of more specifically cleaving one of the mutant mtDNA and wild-type mtDNA.

[0018] (11) According to another aspect of the present disclosure, a pharmaceutical composition can be provided.The pharmaceutical composition comprises any one of the TAL effector nuclease pairs described in (1) to (8) above, the nucleic acid composition described in (9) above, or the vector described in (10) above. According to this pharmaceutical composition, it is possible to more specifically cleave either mutant mtDNA or wild-type mtDNA.

[0019] It should be noted that this disclosure can be implemented in various ways. For example, it can be implemented as a preventive drug for mitochondrial diseases, a therapeutic drug for mitochondrial diseases, a method for manufacturing a preventive drug for mitochondrial diseases, a method for manufacturing a therapeutic drug for mitochondrial diseases, a method for preventing mitochondrial diseases, a method for treating mitochondrial diseases, a method for delaying the progression of mitochondrial diseases, the use of TAL effector nuclease pairs in the manufacture of therapeutic drugs for mitochondrial diseases, the use of TAL effector nuclease pairs for reducing the proportion of mutant mtDNA in mitochondrial diseases, etc. Brief Description of the Drawings

[0020] FIG1 is an explanatory diagram schematically showing the TALEN pair cleaving DNA.

[0021] FIG2 is an explanatory diagram showing the RVD of the TALEN pair used to cleave mutant mtDNA in SSA detections 1 and 5 together with the target sequence.

[0022] Figure 3 is an explanatory diagram showing the RVD of the TALEN pair used to cleave wild-type mtDNA in SSA tests 1 and 5 together with the target sequence.

[0023] Figure 4 is an explanatory diagram showing the RVD of the TALEN pair used in SSA tests 2-4 together with the target sequence.

[0024] Figure 5 is an explanatory diagram showing an overview of the SSA tests.

[0025] Figure 6 is an explanatory diagram showing the DNA cleavage activity of the TALEN pair used to cleave mutant mtDNA in SSA test 1.

[0026] Figure 7 is an explanatory diagram showing the cleavage specificity against mutant mtDNA.

[0027] Figure 8 is an explanatory diagram showing the DNA cleavage activity of the TALEN pair used to cleave wild-type mtDNA in SSA test 1.

[0028] Figure 9 is an explanatory diagram showing the cleavage specificity against wild-type mtDNA.

[0029] Figure 10 is an explanatory diagram showing the results of SSA test 2.

[0030] Figure 11 is an explanatory diagram showing the results of SSA test 3.

[0031] Figure 12 is an explanatory diagram showing the results of SSA detection 4.

[0032] Figure 13 is an explanatory diagram showing the results of cleavage activity in SSA detection 5.

[0033] Figure 14 is an explanatory diagram showing the cleavage specificity brought about by the TALEN pair used to cleave mutant mtDNA.

[0034] Figure 15 is an explanatory diagram showing the cleavage specificity brought about by the TALEN pair used to cleave wild-type mtDNA.

[0035] Figure 16 is an explanatory diagram showing the inhibition of TALEN non-specific cleavage brought about by amino acid modifications in the FokI region.

[0036] Figure 17 is an explanatory diagram showing the effect of mutation rate change when using mpTALEN for cleaving mutant mtDNA.

[0037] Figure 18 is an explanatory diagram showing the effect of mutation rate change when using mpTALEN for cleaving wild-type mtDNA. Detailed Description

[0038] The inventors of this application attempted to design TAL effector nuclease (Transcription activator-like effector nuclease, hereinafter also referred to as "TALEN") pairs that specifically bind to and cleave mtDNA associated with mitochondrial disease-induced mutations, as shown in the embodiments described below. The results showed that by using an RVD that recognizes the bases of the target mtDNA sequence, which is different from the commonly used RVD, the cleavage specificity of mtDNA brought about by the TALEN pair can be improved, thus completing the invention of this application. The inferred mechanism that can improve cleavage specificity is not yet clear, but the following inferred mechanism is speculated. That is, it is believed that: targeting the bases of point mutation sites that induce mitochondrial diseases, by using an RVD different from the commonly used RVD to recognize and adjust the binding ability of the bases to TALE, the TALEN pair can bind more specifically to mtDNA, thereby improving the cleavage specificity.

[0039] According to one aspect of the present disclosure, a TAL effector nuclease pair can be provided. The TALEN pair comprises a first TALEN monomer and a second TALEN monomer. The first TALEN monomer and the second TALEN monomer each have: a DNA-binding domain comprising a repeat variable di-residues (RVD) and a DNA-cleaving domain of a FokI endonuclease. It should be noted that the DNA-binding domain is also referred to as TALE.

[0040] FIG1 is an illustration schematically showing the TALEN pair cleaving DNA. The TALEN monomer consists of a single polypeptide chain. The first TALEN monomer binds to the target sequence on the sense strand in its DNA-binding domain, and the second TALEN monomer binds to the target sequence on the antisense strand in its DNA-binding domain. RVDs are variable sites within repeating units of 20–34 amino acids, typically corresponding to amino acid residues at positions 12 and 13 of that repeating unit. Each RVD recognizes one base, thereby enabling the DNA-binding domain to bind to the target sequence. The DNA-binding domains of the first and second TALEN monomers in this disclosure specifically bind to target mtDNA sequences of 8–15 bases, respectively, based on the RVDs of the modules contained in the TALE.The DNA-binding domain of the first TALEN monomer more preferably binds specifically to a target mtDNA sequence of 9-13 bases, further preferably to a target mtDNA sequence of 10-12 bases, and even more preferably to a target mtDNA sequence of 10-11 bases. The DNA-binding domain of the second TALEN monomer more preferably binds specifically to a target mtDNA sequence of 9-14 bases, further preferably to a target mtDNA sequence of 11-14 bases, and even more preferably to a target mtDNA sequence of 11-12 bases. The lengths of the target mtDNA sequences specifically bound by the DNA-binding domains of the first and second TALEN monomers are more preferably 9-13 bases for the first TALEN monomer and 9-14 bases for the second TALEN monomer, more preferably 10-12 bases for the first TALEN monomer and 11-14 bases for the second TALEN monomer, and even more preferably 10-11 bases for the first TALEN monomer and 11-12 bases for the second TALEN monomer. In this disclosure, the target sequences of the first and second TALEN monomers are spaced 12-20 bases apart. The target sequences of the first and second TALEN monomers are preferably spaced 12-15 bases apart, more preferably 12-14 bases apart, and even more preferably 13 bases apart. In other words, the spacers of the TALEN pairs in this disclosure are 12-20 bases, preferably 12-15 bases, more preferably 12-14 bases, and even more preferably 13 bases. In this spacer, the DNA-cutting domains of the FokI endonuclease, respectively, of the first TALEN monomer and the second TALEN monomer are opposite each other to form a dimer, which can cleave double-stranded DNA.

[0041] The TALEN pair of this disclosure can change the ratio of mutant mtDNA to wild-type mtDNA by binding to mitochondrial DNA (mtDNA). As a result, it can be used to reproduce the symptoms of mitochondrial diseases caused by mutant mtDNA, and is expected to be used to elucidate the symptoms and develop treatment methods. There are no particular limitations on the mitochondrial diseases caused by mutant mtDNA. Examples include mitochondrial encephalopathy with hyperlactatemia and stroke-like attacks (MELAS), myoclonic epilepsy with broken red fiber syndrome (MERRF), chronic progressive extraocular muscle paralysis (CPEO), Leigh encephalopathy, Leber hereditary optic neuropathy (LHON), Kearns-Sayre syndrome (KSS), Pearson syndrome (PS), mitochondrial diabetes, etc. Among these, MELAS and mitochondrial diabetes are preferred.

[0042] There is no particular limitation as long as the mutated mtDNA is an mtDNA with a base sequence mutation that is a factor in the pathogenesis of mitochondrial diseases. The TALEN of this disclosure specifically binds to and cleaves mtDNA associated with mitochondrial disease-induced mutations that have a base of A (adenine) or G (guanine) in the wild type before mutation. (See specification 4 / 14 page 7 CN 121666451) The mutations induced by mitochondrial diseases, where the pre-mutant base is A, are not specifically limited. For example, in the case of humans, examples include A608G, A1116G, A1555G, A1640G, A3243G, A3251G, A3252G, A3260G, A3274G, A3280G, A3288G, A3302G, A3995G, A4136G, A4267G, A4269G, A4295G, A4300G, A4317G, A4917G, A7443G, A7543G, A7445G, A8296G, A8326G, and A8344G. Models include A8348G, A9016G, A10543G, A11084G, A12146G, A12320G, A12770G, A13514G, A13528G, A14495G, A15579G, and A15923G.As a mutation induced by mitochondrial diseases where the pre-mutant base is G, there are no specific limitations. For example, in the case of humans, examples include G583A, G611A, G617A, G1606A, G1642A, G1644A, G3196A, G3242A, G3244A, G3249A, G3255A, G3376A, G3380A, G3460A, G3635A, G3697A, G3700A, G3733A, G3946A, G3959A, G4284A, G4298A, G4309A, G4332A, G4450A, G5244A, G5521A, G5532A, and G5540A. G5549A, G5703A, G5920A, G5968A, G6708A, G6930A, G7023A, G7497A, G7896A, G8313A, G8328A, G8342A, G8361A, G8363A, G9438A, G9952A, G10197A, G11778A, G11832A, G12147A, G12183A, G12207A, G12315A, G12294A, G13042A, G13051A, G13513A, G13730A, G14279A, G14453A, G14459A, G14846A, G15059A, G15084A, G15150A, G15168A, G15242A, G15243A, G15498A, G15615A, G15723A, G15762A, G15915A, G15995A, etc. The mutated mtDNA typically contains one type of base sequence mutation, but can also contain two or more.

[0043] In the above description of mutations, the first letter indicates the base before the mutation, the middle number indicates the base position of the mutated object, i.e., the base number of the mtDNA, and the last letter indicates the base after the mutation. The sequence of human wild-type mtDNA is represented by accession number NC_012920.1 in the GenBank (registered trademark) database published by NCBI (National Center for Biological Information).

[0044] The RVDs contained in the DNA-binding domains of the first TALEN monomer and the second TALEN monomer respectively include: a first RVD that recognizes a base that induces a mitochondrial disease mutation site, and a second RVD that recognizes a base other than the mitochondrial disease mutation site. In this disclosure, amino acid residues in the amino acid sequence are represented by single letters representing amino acids.That is, A represents alanine, R represents arginine, N represents asparagine, D represents aspartic acid, C represents cysteine, Q represents glutamine, E represents glutamic acid, G represents glycine, H represents histidine, I represents isoleucine, L represents leucine, K represents lysine, M represents methionine, F represents phenylalanine, P represents proline, S represents serine, T represents threonine, W represents tryptophan, Y represents tyrosine, and V represents valine.

[0045] The first RVD is at least one of NM (asparagine-methionine) which recognizes adenine, WK (tryptophan-lysine) which recognizes guanine, and LK (leucine-lysine) which recognizes guanine. Therefore, in the TALEN pair used to cleave mutant mtDNA with a base of G before mutation and a base of A after mutation, adenine is recognized by NM. Similarly, in the TALEN pair used to cleave wild-type mtDNA associated with mitochondrial disease-induced mutations where the pre-mutation base is A and the post-mutation base is G, NM also recognizes adenine. Additionally, in the TALEN pair used to cleave mutated mtDNA where the pre-mutation base is A and the post-mutation base is G, WK or LK recognizes guanine. Similarly, in the TALEN pair used to cleave wild-type mtDNA associated with mitochondrial disease-induced mutations where the pre-mutation base is G and the post-mutation base is A, WK or LK also recognize guanine.

[0046] The second RVD that recognizes bases other than the mitochondrial disease-induced mutation site is equivalent to the commonly used RVD. The second RVD recognizes adenine with NI (asparagine-isoleucine) and guanine with NN (asparagine-asparagine). Additionally, the second RVD recognizes cytosine with HD (histidine-aspartic acid) and thymine with NG (asparagine-glycine). Therefore, in the TALEN pairs disclosed herein, NM, WK, or LK are used to identify the bases at mitochondrial disease-induced mutation sites, and NI, NN, HD, and NG are used to identify bases other than mitochondrial disease-induced mutation sites.

[0047] In the case of mitochondrial disease-induced mutation to A3243G mutation, the RVD in the first TALEN monomer is preferably any one of NN-HD-NI-NN-WK-NN-HD-HD-HD, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD, NN-NN-HD-NI-NN-NM-NN-HD-HD-HD, NN-NN-HD-NI-NN-WK-NN-HD-HD-HD-HD-HD-NN, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-HD-NN and NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN, more preferably NN-NN-HD-NI-NN-WK-NN-HD-HD-HD-HD-NN, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-HD-NN and NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN. Any one of NN, NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-NN and NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN. The RVD in the second TALEN monomer paired with such a first TALEN monomer is preferably NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG, NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN, NN-NG-NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN and NN-NG- Any one of NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG, more preferably NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG, NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN and NN-NG-NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG, more preferably NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG. The above descriptions of RVD all indicate that the sequence from the N-terminus to the C-terminus binds along the 5'-3' direction of the target sequence of the mtDNA.

[0048] In the DNA-binding domains of the first TALEN monomer and the second TALEN monomer, the amino acid sequence other than RVD in the repeat unit can be designed based on known information. For example, the Platinum TALEN design method can be used for design.

[0049] In this disclosure, the DNA cleaving domains of the FokI endonuclease in the first TALEN monomer and the second TALEN monomer preferably have different amino acid sequences and form heterodimers.Based on this configuration, DNA cleavage activity is not exhibited even when the first TALEN monomers or the second TALEN monomers form homodimers with each other, thus inhibiting non-specific DNA cleavage. The DNA cleavage domains of the FokI endonuclease in the first and second TALEN monomers preferably contain three amino acid mutations relative to the wild-type amino acid sequence shown in Serial No. 16. There are no particular limitations on the three amino acid mutations relative to the wild-type, but it is preferred that one of the FokI endonuclease DNA cleavage domains contains a so-called KKR mutation, and the other contains a so-called ELD mutation. The KKR mutation refers to the mutations E109K, H156R, and I157K in the DNA cleavage domain of the FokI endonuclease, as shown in Serial No. 17, and the ELD mutation refers to the mutations Q105E, N115D, and I118L in the DNA cleavage domain of the FokI endonuclease, as shown in Serial No. 18. In the above description of mutations, the first letter represents the amino acid residue before the mutation, the middle number represents the amino acid number in the DNA cleavage domain of the FokI endonuclease, and the last letter represents the amino acid residue after the mutation.

[0050] In the case of mitochondrial disease-induced mutation A3243G mutation, the first TALEN monomer is preferably any one of the amino acid sequences shown in any one of sequence numbers 1 to 3, an amino acid sequence having more than 90% homology with the amino acid sequences shown in any one of sequence numbers 1 to 3, or an amino acid sequence in which one or more amino acid residues are missing, replaced, or added in the amino acid sequences shown in any one of sequence numbers 1 to 3. Furthermore, the second TAL effector nuclease monomer is preferably any one of the amino acid sequences shown in sequence number 4, sequence number 19, and sequence number 20, an amino acid sequence having more than 90% homology with the amino acid sequence shown in sequence number 4, sequence number 19, and sequence number 20, or an amino acid sequence in which one or more amino acids are missing, substituted, or added, more preferably the amino acid sequence shown in sequence number 4, an amino acid sequence having more than 90% homology with the amino acid sequence shown in sequence number 4, or an amino acid sequence in which one or more amino acids are missing, substituted, or added, more preferably the amino acid sequence shown in sequence number 4, an amino acid sequence having more than 90% homology with the amino acid sequence shown in sequence number 4, or an amino acid sequence in which one or more amino acids are missing, substituted, or added, more preferably the amino acid sequence shown in sequence number 4, an amino acid sequence having more than 90% homology with the amino acid sequence shown in sequence number 4, or an amino acid sequence in which one or more amino acids are missing, substituted, or added, more preferably the amino acid sequence shown in sequence number 4.

[0051] In this disclosure, "homology" of amino acid sequences refers to the maximum homology (%) of the sequences obtained by aligning (sequence alignment) the two sequences to be compared by importing them into the empty space specification page 6 / 14 9 CN 121666451 A as needed.The homology of amino acid sequences can be calculated, for example, using blastn from NCBI BLAST (http: / / blast.ncbi.nlm.nih.gov / ) with the BLAST algorithm installed. In this disclosure, from the viewpoint of suppressing the reduction of specificity, the homology of amino acid sequences is preferably 92% or more, more preferably 94% or more, further preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, particularly more preferably 98% or more, and especially preferably 99% or more.

[0052] In this disclosure, "one or more amino acid residues" is preferably 1 to 10 amino acid residues, more preferably 1 to 8 amino acid residues, further preferably 1 to 6 amino acid residues, and even more preferably 1 to 3 amino acid residues. The deletion, substitution, or addition of amino acid residues is preferably in regions far from the coding region of RVD and the region encoding the active site of the FokI endonuclease. In addition, the substitution of amino acid residues is preferably a conserved substitution to an amino acid having a similar side chain. As a conservative substitution, examples include substitutions of amino acid residues with basic side chains such as K, R, and H; substitutions of amino acid residues with acidic side chains such as D and E; substitutions of amino acid residues with non-electrically charged polar side chains such as G, N, Q, S, T, Y, and C; substitutions of amino acid residues with non-polar side chains such as A, V, L, I, P, F, M, and W; substitutions of amino acid residues with β-branched side chains such as T, V, and I; and substitutions of amino acid residues with aromatic side chains such as Y, F, W, and H.

[0053] The first TALEN monomer and the second TALEN monomer constituting the TALEN pair of this disclosure can be chemically modified as long as they have the activity of specifically cleaving mutant mtDNA or wild-type mtDNA when paired.

[0054] For example, the C-terminus of the first TALEN monomer and the second TALEN monomer can also be a carboxyl group (-COOH), a carboxylic acid ester (-COO-), an amide (-CONH2), an ester (-COOR), etc. The R group in the ester is not particularly limited, and can be, for example, C1-6 alkyl groups such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; C3-8 cycloalkyl groups such as cyclopentyl and cyclohexyl; C6-12 aryl groups such as phenyl and α-naphthyl; phenyl-C1-2 alkyl groups such as benzyl and phenethyl; C7-14 aryl groups such as α-naphthylmethyl and α-naphthyl-C1-2 alkyl; neopentyloxymethyl, etc. Additionally, for example, the carboxyl group (or carboxylic acid ester) other than the C-terminus of the first and second TALEN monomers can be amidated or esterified. In this case, the ester is not particularly limited, and can be, for example, the same ester as the one with the C-terminus described above.

[0055] Furthermore, for example, the N-terminal amino groups of the first TALEN monomer and the second TALEN monomer may be protected by a protecting group, or they may be in the form of pyroglutamylation of the N-terminal glutamine residues that can be cleaved in vivo. Additionally, for example, the substituents on the side chains of the amino acids within the first TALEN monomer and the second TALEN monomer may be protected by a protecting group, or they may be complex proteins such as so-called glycoproteins with attached sugar chains. The substituents are not particularly limited, and examples include -OH, -SH, amino, imidazole, indole, guanidinium, etc. The protecting groups are not particularly limited, and examples include C1-6 acyl groups such as formyl, acetyl, etc.

[0056] Furthermore, for example, the first TALEN monomer and the second TALEN monomer may be attached with known protein tags, signal sequences, or other polypeptides. The protein tags are not particularly limited, and examples include biotin, His tags, FLAG tags, Halo tags, MBP tags, HA tags, Myc tags, V5 tags, PA tags, etc. As a signal sequence, there is no particular limitation; for example, MTS (mitochondrial targeting sequence) can be cited. From the viewpoint of enabling it to function within the mitochondria, the first TALEN monomer and the second TALEN monomer preferably have an MTS attached, more preferably an MTS attached to the N-terminal side. Furthermore, from the same viewpoint, it is preferable not to contain a nuclear localization signal.

[0057] Additionally, for example, the first TALEN monomer and the second TALEN monomer may also be in the form of a pharmaceutically acceptable salt of an acid or base. There is no particular limitation as long as the salt is pharmaceutically acceptable; either an acidic salt or a basic salt can be used. As an acidic salt, there is no particular limitation; for example, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate can be cited; organic acid salts such as acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, and p-toluenesulfonate can be cited; and amino acid salts such as aspartate and glutamate can be cited. Furthermore, as a basic salt, there are no particular limitations as specified on page 7 / 14 of the specification (CN 121666451 A). For example, alkali metal salts such as sodium salts and potassium salts, and alkaline earth metal salts such as calcium salts and magnesium salts can be mentioned. Additionally, for example, the first TALEN monomer and the second TALEN monomer can be in the form of a solvate. As a solvent, there are no particular limitations as long as it is pharmaceutically permissible; for example, water, ethanol, glycerol, acetic acid, etc., can be mentioned.

[0058] According to another aspect of this disclosure, a nucleic acid composition is provided.The nucleic acid composition comprises a first nucleic acid encoding a first TAL effector nuclease monomer and a second nucleic acid encoding a second TAL effector nuclease monomer. The target sequence of the first TAL effector nuclease monomer is spaced 12 to 20 bases from the target sequence of the second TAL effector nuclease monomer. The first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have: a DNA-binding domain containing an RVD that binds to DNA of 8 to 15 bases, and a DNA-cutting domain of a FokI endonuclease. The RVD comprises a first RVD that recognizes a mitochondrial disease-induced mutation site and a second RVD that recognizes bases other than the mitochondrial disease-induced mutation site. The first RVD is at least one of NM (adenine), WK (guanine), and LK (guanine). The second RVD recognizes adenine by NI and guanine by NN.

[0059] In this disclosure, the first nucleic acid and the second nucleic acid are preferably mRNA. In addition to the sequences encoding the first TAL effector nuclease monomer or the second TAL effector nuclease monomer, the first and second nucleic acids may also contain, for example, signal sequences, promoters, etc., and preferably include MTS as signal sequences. There are no particular limitations on the promoter; for example, it can be a pol II lineage promoter. Examples of pol II lineage promoters include CMV promoters, EF1 promoters, SV40 promoters, MSCV promoters, hTERT promoters, β-actin promoters, CAG promoters, etc.

[0060] The first and second nucleic acids may contain multiple cloning sites (MCS), drug resistance genes, origins of replication, etc., as needed. For example, in a configuration where the first and second nucleic acids are sequentially configured with the promoter and the coding sequences of the first TAL effector nuclease monomer or the second TAL effector nuclease monomer from the 5' side, the MCS can be positioned between the promoter and the coding sequence, on the 3' side of the coding sequence. The MCS is preferably positioned adjacent to the promoter and the coding sequence. MCS is not particularly limited as long as it contains multiple restriction enzyme sites. For example, it is preferred to contain 2 to 50, more preferably 2 to 20, and more preferably 2 to 10 restriction enzyme sites. As for drug resistance genes, there are no particular limitations. Examples include ampicillin resistance genes, chloramphenicol resistance genes, tetracycline resistance genes, neomycin resistance genes, erythromycin resistance genes, spectinomycin resistance genes, kanamycin resistance genes, hygromycin resistance genes, and puromycin resistance genes. It should be noted that the first and second nucleic acids can be composed of different nucleic acids, or they can be composed of a single nucleic acid containing both the first and second nucleic acids.

[0061] According to another aspect of this disclosure, a vector containing the above-described nucleic acid composition can be provided.As a carrier, there are no particular limitations. For example, plasmid vectors such as animal cell expression plasmids can be cited; viral vectors such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpesviruses, and Sendai viruses can be cited; Agrobacterium vectors can be cited, etc.

[0062] According to another aspect of this disclosure, a pharmaceutical composition comprising the above-mentioned TALEN pairs, the above-mentioned nucleic acid composition, or the above-mentioned carrier can be provided. The pharmaceutical composition can be formulated by appropriately combining a pharmaceutically acceptable carrier or additive. Specifically, it can be formulated into oral dosage forms such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions; and non-oral dosage forms such as injections, infusions, suppositories, ointments, and patches. The proportion of carriers or additives can be appropriately set based on the range commonly used in the pharmaceutical field. As a carrier or additive, there are no particular limitations. Examples include various carriers, excipients, binders, solvents, solubilizers, salt-forming agents, salts, buffers, viscosity modifiers, hardness modifiers, pH modifiers, gelling agents, emulsifiers, solubilizers, wetting agents, dispersants, disintegrants, absorption promoters, lubricants, antioxidants, preservatives, fillers, colorants, flavoring agents, fragrances, adjuvants, etc.

[0063] The pharmaceutical composition disclosed herein can, for example, reduce the proportion of mutant mtDNA in heterogeneous mtDNA by specifically binding to and cleaving mutant mtDNA. As a result, the pathogenesis of mitochondrial diseases can be inhibited, and therefore it is expected to be used as a preventive medicine for mitochondrial diseases. In addition, as a result of being able to reduce the proportion of mutant mtDNA, it is expected to be used as a therapeutic medicine for mitochondrial diseases. It should be noted that the treatment of mitochondrial diseases includes delaying the progression of mitochondrial diseases.

[0064] According to another aspect of this disclosure, a method for the prevention or treatment of mitochondrial diseases can be provided. The method includes the following steps: administering the above-described pharmaceutical composition to a subject having a mitochondrial disease-inducing mutation containing a site where the wild-type base A is changed to G or a site where the wild-type base G is changed to A.

[0065] Examples

[0066] Hereinafter, the present invention will be described in more detail according to examples, but the present invention is not limited to the following examples.

[0067] 1. Samples and methods

[0068] (1) Preparation and culture of human iPS cells

[0069] Skin biopsy samples were obtained from diabetic patients with an A3243G mutation in mtDNA. The patients' fibroblasts were proliferated in DMEM medium containing 10% FBS and 1% antibiotic solution (Antibiotic Antimycotic Solution, Sigma).Five × 10⁵ fibroblasts were transformed using free vectors (pCXLE-hOCT3 / 4-shp53-F, Addgene #27077; pCXLE-hSK, #27078; pCXLE-hUL, #27080, provided by Shinya Yamanaka) with six reprogramming factors (SOX2, KLF4, OCT3 / 4, L-MYC, LIN28, and p53-shRNA). During transformation, Nucleofector 2b (manufactured by Lonza, a registered trademark) was used in conjunction with the Amaxa Human Dermal Fibroblast Nucleofector Kit (manufactured by Lonza, "Nucleofector" is a registered trademark). Seven days after inoculation, the fibroblasts were seeded onto a mitomycin C-treated SNL feeder layer. The day after inoculation, the culture medium was replaced with primate iPS cell culture medium (REPROCELL) supplemented with basic fibroblast growth factor (bFGF) (Fujifilm & Kogyo). Several weeks later, the observed multiple ESC-like colonies (iPS cell colonies) were mechanically peeled off and transferred to new culture plates. It should be noted that when taking iPS cell colonies, they were treated with CTK solution containing 0.1 mg / mL collagenase IV (Gibco), 0.25% trypsin (Gibco), 0.1 mM calcium chloride (Wako), and 20% KSR (Gibco).

[0070] (2) DNA isolation

[0071] Genomic DNA containing mtDNA was isolated from fibroblasts and iPS cells using NucleoSpin Tissue XS (Macherey-Nagel) according to the manufacturer's specifications.

[0072] (3) Analysis of mtDNA heterogeneity based on PCR-RFLP

[0073] DNA was amplified using the primer set of Mt3150-F primer (Sequence No. 5: TACTTCACAAAGCGCCTTCC) and mt3294-R primer (Sequence No. 6: AGGAATTGAACCTCTGACTG). PCR conditions: 35 cycles of 94℃ for 1 minute, 94℃ for 30 seconds, 57℃ for 30 seconds, and 72℃ for 30 seconds. In the presence of the A3243G mutation, the 145bp PCR product was cut into two fragments, 95bp and 50bp, by the restriction endonuclease HaeIII (manufactured by NEB). The PCR products digested by the restriction endonuclease HaeIII were separated by 3% agarose gel and stained with ethidium bromide. The signal intensity ratio was analyzed using ImageJ software (Windows version).

[0074] (4) Design of TAL effector nuclease pairs

[0075] TALEN pairs for cleaving mutant mtDNA and TALEN pairs for cleaving wild-type mtDNA were designed respectively.

[0076] Figure 2 is an illustration showing the RVD of the TALEN pairs used for cleaving mutant mtDNA in SSA detections 1 and 5 together with the target sequence. Figure 3 is an illustration showing the RVD of the TALEN pairs used for cleaving wild-type mtDNA in SSA detections 1 and 5 together with the target sequence. Figure 4 is an illustration showing the RVD of the TALEN pairs used in SSA detections 2 to 4 together with the target sequence. For convenience, the bases of the mitochondrial disease-induced mutation sites are indicated by arrows in Figures 2 to 4.

[0077] In the SSA detection 1 described later, the RVD of the first TALEN monomer used to cut the mutant mtDNA is as shown in Figure 2, starting from the N-terminus: NN-NN-HD-NI-NN-LK-NN-HD-HD-HD-HD-NN (hereinafter, this monomer is also referred to as “PL6LK” on page 9 / 14 of the specification, CN 121666451 A) and NN-NN-HD-NI-NN-LK-NN-HD-HD-HD (hereinafter, this monomer is also referred to as “CL6LK”). The RVD of the control is as follows, starting from the N-terminus: NN-NN-HD-NI-NN-NN-NN-HD-HD-HD-HD-NN (hereinafter, this monomer is also referred to as “PL”) and NN-NN-HD-NI-NN-NN-NN-HD-HD-HD (hereinafter, this monomer is also referred to as “CL”). The RVD of the first TALEN monomer used to cleave wild-type mtDNA is shown in Figure 3, starting from the N-terminus: NN-NN-HD-NI-NN-NM-NN-HD-HD-HD-NN (hereinafter, this monomer will also be referred to as "PLW6NM"). The RVD of the control is shown from the N-terminus: NN-NN-HD-NI-NN-NI-NN-HD-HD-HD-NN (hereinafter, this monomer will also be referred to as "PLW"). The RVD of the second TALEN monomer is shown in Figures 2 and 3, starting from the N-terminus: NN-NG-NI-NI-NN-NG-NG-NG-NI-NI-NN (hereinafter, this monomer will also be referred to as "MR").

[0078] In the SSA detection 2 and subsequent experiments described later, the RVD of the first TALEN monomer used to cleave the mutant mtDNA is NN-NN-HD-NI-NN-WK-NN-HD-HD-HD-NN (hereinafter, this monomer will also be referred to as "PL6WK") or PL6LK as described above, as shown in Figures 2 and 4. The RVD of the first TALEN monomer used to cleave the wild-type mtDNA is PLW6NM as described above, as shown in Figures 3 and 4.The RVD of the second TALEN monomer is shown in Figures 2 to 4. From the N-terminus side, it is NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG (hereinafter, this monomer will also be referred to as "JR"), NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN (hereinafter, this monomer will also be referred to as "OR"), NN-NG-NI-NI-NI-NN-NG-NG-NG-NG-NI-NI-NN-NG (hereinafter, this monomer will also be referred to as "QR") or the above MR. In the following description, for TALEN pairs, monomers constructed as p["first TALEN monomer" / "second TALEN monomer"] are used.

[0079] (5) Construction of TALEN expression plasmid

[0080] The TALEN expression plasmid was constructed using the Platinum Gate TALEN kit (Platinum Gate TALEN kit, #1000000043, made by Addgene). As described in the manufacturer's specifications for the Platinum Gate TALEN kit, the Golden Gate method was used in the 4-module assembly and the final TALEN vector assembly using the 4-module conjugation plasmid. The restriction endonuclease BsaI-HFv2 (NEB) was used in the first stage of Golden Gate cloning. During 4-module assembly, the p2NI vectors, specifically p2WK, p2LK, and p2NM vectors required for introducing WK, LK, and NM RVDs into the second module, were modified. DNA fragments containing RVDs modified to WK, LK, and NM (synthesized by Azenta) were introduced into p2NI vectors digested with HindIII and AgeI using the In-Fusion HD cloning kit (Clontech Laboratories). The target vector for expressing platinum TALEN (pTALEN) monomers had a +136 / +63 scaffold sequence under the control of the CAG promoter. The target vector for expressing the mpTALEN monomer was modified with a mitochondrial target sequence (MTS) containing ATP5B and an N-terminal V5-tag. The target vector with the heterodimer FokI (ELD / KKR) scaffold sequence was prepared by modifying the mpTALEN target vector. A DNA fragment containing an ELD mutation, synthesized by Azenta, was inserted into the mpTALEN target vector digested with BamHI and BstXI using the In-Fusion HD cloning kit (Clontec Laboratories).Three DNA fragments containing the KKR mutation were amplified by PCR using the following primer sets: BamHI_Fok1_fwd primer (serial number 7: ACCAACAGAAGGATCCCCGA) and K1-Fok1_rev primer (serial number 8: ATTTCCTTGACATAACGTTGCATCTC), K1-Fok2_fwd primer (serial number 9: TATGTCAAGGAAAATCAGACCAGGAAC) and R2K3-Fok2_rev primer (serial number 10: TTCGTCTTTCTATTCAACCGTGTGAGCTG), R2K3-Fok3_fwd primer (serial number 11: GAATAGAAAGACGAACTGCAA TGGTGCG), and SexAI_Fok3_rev primer (serial number 12: ACTTTCCACACCTGGTTGCT). These fragments were then used in the In-Fusion HD cloning kit (Clontech). (manufactured by Laboratories) was inserted into the mpTALEN target vector digested by BamHI and SexAI.

[0081] (6) Immunocytochemical analysis manual 10 / 14 pages 13 CN 121666451 A

[0082] Immunocytochemical analysis confirmed that the TALEN monomer expressed by the prepared expression vector co-localized with the mitochondrial marker (Tom20) and was not observed in the cell nucleus. Immunocytochemical analysis was performed as follows. Cells were fixed with 4% paraformaldehyde / PBS for 30 minutes and incubated with PBS containing 0.2% Triton X-100 for 10 minutes. After blocking with 2% BSA / PBS for 1 hour, the cells were incubated with primary antibody diluted with blocking buffer and washed with PBS. Finally, the cells were incubated with secondary antibody, washed with PBS, and mounted with ProLong Diamond Antifade Mountant (manufactured by Molecular Probes) containing DAPI. Immunologically reactive cells were visualized using an LSM710 Laser Scanning Microscope (Carl Zeiss) or a Biorevo BZ-9000 fluorescence microscope (Keyence).

[0083] (7) Single-chain annealing (SSA) detection using HEK293T cells

[0084] Figure 5 is an explanatory diagram showing the outline of SSA detection.DNA cleavage activity of TALEN pairs can be evaluated using SSA assay (Sakuma T, et al. (2013) Genes to cells: devoted to molecular & cellular mechanisms 18(4): 315-326). Using primer sets of XmaI-A3243_F (Sequence No. 13: TTACCCGGGTATTATACCCACACCCACCC) and XmaI-A3243AWT_R3 (Sequence No. 14: TTACCCGGGTGAAC CTCTGACTGTAAAGTTTTAAGTTTTATGCGATTACCGGGCT) or XmaI-A3243G_R3 (Sequence No. 15: TTAC CCGGGTGAACCTCTGACTGTAAAGTTTTAAGTTTTATGCGATTACCGGGCC), a portion of the mtDNA sequence containing TALEN-targeted m.3243A or m.3243G was amplified by PCR and inserted into the XmaI site between the bisected luciferase elements of the pGL4-SSA reporter gene plasmid. Using Lipofectamine LTX (Invitrogen), three plasmids consisting of a TALEN expression plasmid, a reporter gene plasmid, and a reference plasmid for dual-luciferase detection (pRL-CMV, Promega) were introduced into HEK293T cells. Twenty-four hours after introduction, dual-luciferase detection was performed using a Dual-Glo luciferase assay system (Promega). Luminescence detection was performed using an ARVO X5 luminometer (Perkin-Elmer) or a VICTOR Nivo Multimode Microplate reader (Perkin-Elmer).

[0085] (8) Transfection and Sorting

[0086] For HEK293T and HeLa cells, transfection was performed using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer's specifications. Patient-derived iPS cells with the m.3243A>G mutation were cultured in a feeder-free environment according to the method described in Nakagawa M, et al. (2014) Scientific reports 4:3594 for the introduction of the mpTALEN plasmid. After removing the feeder cells, the cells were dissociated into single cells by treating with 0.5× TrypLE Select (manufactured by Gibco, TrypLE is a registered trademark) at 37°C for approximately 2 minutes.Single cells were seeded into iMatrix-511 (Matrixome) coated culture dishes and cultured in StemFit AK02N medium (ReproCell). One day later, 1.67 μg each of pCAGGS-EGFP and mpTALEN plasmids were introduced into iPS cells using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer's instructions. Two days after introduction, cells were harvested and sorted using Moflo Astrios (Beckman Coulter) equipped with Summit acquisition software (Beckman Coulter). Dead cells and debris stained with iodopropimidium (PI) solution (Dongjin Chemical Research Institute) were removed, and the sorting gate was set based on forward and side scattering and EGFP expression levels. EGFP-positive and PI-negative cells were directly sorted into StemFit AK02N medium supplemented with 10 μM Y-27632 (Nacalai Tesque).

[0087] 2. Results

[0088] (1) SSA Detection 1

[0089] Figure 6 is an illustration of the DNA cleavage activity of the TALEN pairs used to cleave mutant mtDNA in SSA Detection 1. Specification 11 / 14 pages 14 CN 121666451 A Figure 7 is an illustration of the cleavage specificity for mutant mtDNA. In Figure 6 and Figures 8, 10-13 described below, the cleavage activity of wild-type (WT) mtDNA sequences containing m.3243A (hereinafter referred to as wild-type mtDNA cleavage activity) and the cleavage activity of mutant (MUT) mtDNA sequences containing m.3243G (hereinafter referred to as mutant mtDNA cleavage activity) are shown for each TALEN pair used in SSA Detection. As TALEN pairs, combinations of PL6LK and MR (referred to as p[PL6LK / MR]), combinations of CL6LK and MR (referred to as p[CL6LK / MR]), combinations of PL and MR as controls (referred to as p[PL / MR]), and combinations of CL and MR (referred to as p[CL / MR]) were used. In Figure 6 and Figures 8, 10-13 described later, "NC" indicates a negative control without TALEN pairs. In Figure 6, the cleavage activity of p[PL6LK / MR] against the mutant mtDNA is expressed as a relative value when the cleavage activity is set to 1. In Figure 7, the cleavage specificity of the m.3243G mutant mtDNA is expressed as the value obtained by dividing the cleavage activity of the mutant mtDNA shown in Figure 6 by the cleavage activity of the wild-type mtDNA.

[0090] Based on the results shown in Figures 6 and 7, the following can be understood.That is, in the control TALEN pairs (p[PL / MR] and p[CL / MR]), the cleavage activity against mutant mtDNA was not different from that against wild-type mtDNA. In contrast, in p[PL6LK / MR] and p[CL6LK / MR], the cleavage activity against mutant mtDNA was higher than that against wild-type mtDNA, resulting in high cleavage specificity against mutant mtDNA. In addition, the cleavage activity against mutant mtDNA in p[PL6LK / MR] and p[CL6LK / MR] was higher than that in p[PL / MR] and p[CL / MR].

[0091] Figure 8 is an illustration of the DNA cleavage activity of the TALEN pairs used to cleave wild-type mtDNA in SSA assay 1. Figure 9 is an illustration of the cleavage specificity against wild-type mtDNA. As TALEN pairs, a combination of PLW6NM and MR (referred to as p[PLW6NM / MR]) and a control combination of PLW and MR (referred to as p[PLW / MR]) were used. In Figure 8, the cleavage activity of p[PLW6NM / MR] against wild-type mtDNA is represented by a relative value when the cleavage activity of wild-type mtDNA is set to 1. In Figure 9, the cleavage specificity of m.3243A wild-type mtDNA is represented by the value obtained by dividing the cleavage activity of wild-type mtDNA by the cleavage activity of mutant mtDNA, as shown in Figure 8.

[0092] Based on the results shown in Figures 8 and 9, the following can be concluded. That is, compared with the control TALEN pair (p[PLW / MR]), p[PLW6NM / MR] has higher cleavage specificity against wild-type mtDNA and also higher cleavage activity against wild-type mtDNA.

[0093] Based on the results of SSA detection 1 described above, it is shown that by using TALEN pairs that identify the bases at the site of point mutations that induce mitochondrial diseases using an RVD different from the commonly used RVD, the cleavage specificity for mutant mtDNA or wild-type mtDNA can be improved. In addition, it is shown that the cleavage activity for mutant mtDNA or wild-type mtDNA can be improved.

[0094] (2) SSA detection 2

[0095] FIG10 is an explanatory diagram showing the results of SSA detection 2. In FIG10, the DNA cleavage activity and cleavage specificity for mutant mtDNA of TALEN pairs used for cleaving mutant mtDNA are shown. In FIG10, DNA cleavage activity is represented by the relative value when the cleavage activity of p[PL6LK / MR] pairs for mutant mtDNA is set to 1, and cleavage specificity is represented by the value obtained by dividing the cleavage activity of mutant mtDNA by the cleavage activity of wild-type mtDNA.According to the results shown in Figure 10, it can be seen that when OR and JR are used as the second TALEN monomers in the TALEN pair used to cleave mutant mtDNA, the cleavage specificity of mutant mtDNA is as excellent as when MR is used. Furthermore, when OR and JR are used as the second TALEN monomers, the cleavage specificity of mutant mtDNA is further improved compared with MR.

[0096] (3) SSA detection 3

[0097] Figure 11 is an explanatory diagram showing the results of SSA detection 3. Figure 11 shows the DNA cleavage activity and cleavage specificity of the TALEN pair used to cleave wild-type mtDNA. In Figure 11, the DNA cleavage activity is represented by the relative value when the cleavage activity of p[PLW6NM / MR] against wild-type mtDNA is set to 1, and the cleavage specificity is represented by the value obtained by dividing the cleavage activity of wild-type mtDNA by the cleavage activity of mutant mtDNA. According to the results shown in Figure 11, it can be seen that when QR and JR are used as the second TALEN monomers in the TALEN pair used to cut wild-type mtDNA (pages 12 / 14 of the instruction manual, CN 121666451 A), the cutting specificity for wild-type mtDNA is as excellent as when MR is used. Furthermore, it can be seen that when QR and JR are used as the second TALEN monomers, the cutting specificity for wild-type mtDNA is further improved compared with MR, and the cutting specificity is particularly excellent when JR is used.

[0098] (4) SSA detection 4

[0099] Figure 12 is an explanatory diagram showing the results of SSA detection 4. Figure 12 shows the DNA cutting activity and cutting specificity for wild-type mtDNA of the TALEN pair used to cut wild-type mtDNA. In Figure 12, DNA cleavage activity is represented by a relative value when the cleavage activity of p[PLW6NM / MR] against wild-type mtDNA is set to 1, and cleavage specificity is represented by the value obtained by dividing the cleavage activity of wild-type mtDNA by the cleavage activity of mutant mtDNA. According to the results shown in Figure 12, it can be seen that when OR is used as the second TALEN monomer, the cleavage specificity is also particularly excellent, just like when JR is used.

[0100] (5) SSA detection 5

[0101] Figure 13 is an explanatory diagram showing the results of cleavage activity in SSA detection 5. As a TALEN pair, PL6WK, PL6LK or PLW6NM is used in combination with JR. In the following description, monomers with ELD mutation or KKR mutation in the DNA cleavage domain are written as "-ELD" or "-KKR" at the end of the monomer. In Figure 13, the cleavage activity when the cleavage activity of p[PL6LK / JR] against mutant mtDNA is set to 1 is represented by a relative value.

[0102] Figure 14 is an illustration of the cleavage specificity brought about by TALEN pairs used to cleave mutant mtDNA.Figure 15 is an illustration of the cleavage specificity of the TALEN pairs used to cleave wild-type mtDNA. In Figure 14, the cleavage specificity of m.3243G mutant mtDNA is represented by the value obtained by dividing the cleavage activity of the mutant mtDNA shown in Figure 13 by the cleavage activity of the wild-type mtDNA. In Figure 15, the cleavage specificity of m.3243A wild-type mtDNA is represented by the value obtained by dividing the cleavage activity of the wild-type mtDNA shown in Figure 13 by the cleavage activity of the mutant mtDNA.

[0103] Based on the results shown in Figures 13 to 15, the following can be concluded. That is, among the TALEN pairs used to cleave mutant mtDNA (p[PL6LK / JR], p[PL6LK-ELD / JR-KKR], p[PL6WK / JR], p[PL6WK-ELD / JR-KKR]), the cleavage activity against mutant mtDNA is higher than that against wild-type mtDNA. Similarly, the TALEN pairs used for cleaving wild-type mtDNA (p[PLW6NM / JR], p[PLW6NM-ELD / JR-KKR]) exhibit higher cleavage activity against wild-type mtDNA compared to their cleavage activity against mutant mtDNA. Therefore, it is demonstrated that the TALEN pairs according to this disclosure can cleave either mutant or wild-type mtDNA with greater specificity. In particular, it is shown that the specificity is further enhanced in TALEN pairs where FokI endonuclease forms heterodimers by combining monomers with ELD mutations in the DNA cleavage domain with monomers with KKR mutations. On the other hand, it is believed that TALEN pairs formed by TALEN monomers with ELD mutations (p[PL6WK-ELD / JR-ELD]) do not form dimers of the enzymatically active FokI endonuclease, resulting in extremely low cleavage activity.

[0104] (6) Changes in the mutation rate of mpTALEN in MELAS-iPS cells

[0105] Figure 16 is an illustration of inhibiting non-specific TALEN cleavage through amino acid modification of the FokI region. Figure 16 schematically shows the structures of Lv-mpTALEN without mutation in the DNA cleavage domain of the FokI endonuclease, Lv-mpTALEN-ELD with ELD mutation, and Lv-mpTALEN-KKR with KKR mutation as TALEN monomers used in the examples. As shown in Figure 16, homodimers formed by monomers without mutation in the FokI region and heterodimers formed by monomers with ELD mutation in the FokI region and monomers with KKR mutation in the FokI region both have enzymatic activity. In contrast, homodimers formed by monomers with ELD mutation in the FokI region and homodimers formed by monomers with KKR mutation in the FokI region do not have enzymatic activity.Therefore, by introducing an ELD mutation into one monomer and a KKR mutation into the other monomer of a TALEN pair, it is expected to be possible to suppress non-specific cleavage of mtDNA.

[0106] Figure 17 is a diagram illustrating the effect of mutation rate change when using mpTALEN for cleaving mutant mtDNA (pages 13 / 14, CN 121666451 A). Figure 18 is an explanatory diagram illustrating the effect of mutation rate change when using mpTALEN for cleaving wild-type mtDNA. In Figures 17 and 18, for each TALEN pair used, the A3243G mutation rate (%) in MELAS-iPS cells on day 2 (day 2) after mpTALEN plasmid introduction and the A3243G mutation rate (%) in MELAS-iPS cells on day 10 (day 10) after mpTALEN plasmid introduction are shown. It should be noted that in Figures 17 and 18, MELAS-iPS cells on day 2 without the mpTALEN plasmid introduced are considered untreated cells, and the A3243G mutation rate (%) in untreated cells is represented by a dashed line.

[0107] Based on the results shown in Figures 17 and 18, the following can be observed. That is, by introducing the mpTALEN plasmid for expressing the TALEN pair that cleaves the mutant mtDNA, a decrease in the A3243G mutation rate was observed compared to untreated cells. Similarly, by introducing the mpTALEN plasmid for expressing the TALEN pair that cleaves the wild-type mtDNA, an increase in the A3243G mutation rate was observed compared to untreated cells. Therefore, according to the TALEN pair, nucleic acid composition, and vector of this disclosure, one of the mutant mtDNA and the wild-type mtDNA can be cleaved more specifically, and the results indicate that the mutation rate in the mtDNA can be altered. It should be noted that, similar to the results of SSA detection 5, no dimer of the enzymatically active FokI endonuclease was formed in the TALEN pairs formed by the TALEN monomers with ELD mutations, and no mtDNA cleavage occurred. The A3243G mutation rate was the same as that of untreated cells.

[0108] The present invention is not limited to the embodiments described above, and can be implemented with various configurations without departing from its spirit. For example, the technical features in the embodiments and examples corresponding to the technical features in the various ways described in the summary column of the invention can be appropriately replaced or combined to solve part or all of the above-described problems, or to achieve part or all of the above-described effects. In addition, any technical feature that is not described as essential in this specification can be appropriately deleted.Instruction manual page 14 / 14, page 17, CN 121666451 A, Figure 1; Instruction manual figure 1 / 17, page 18, CN 121666451 A, Figure 2; Instruction manual figure 2 / 17, page 19, CN 121666451 A, Figure 3; Instruction manual figure 3 / 17, page 20, CN 121666451 A, Figure 4; Instruction manual figure 4 / 17, page 21, CN 121666451 A, Figure 5; Instruction manual figure 5 / 17, page 22, CN 121666451 A, Figure 6; Instruction manual figure 6 / 17, page 23, CN 121666451 A, Figure 7; Instruction manual figure 7 / 17, page 24, CN 121666451 A, Figure 8; Instruction manual figure 8 / 17, page 25, CN 121666451 A, Figure 9; Instruction manual figure 9 / 17, page 26, CN 121666451 A, Figure 10; Figure 11 Figure 12 of the instruction manual, page 27 of 10 / 17, CN 121666451 A; Figure 13 of the instruction manual, page 28 of 11 / 17, CN 121666451 A; Figure 14 of the instruction manual, page 30 of 13 / 17, CN 121666451 A; Figure 15 of the instruction manual, page 31 of 14 / 17, CN 121666451 A; Figure 16 of the instruction manual, page 32 of 15 / 17, CN 121666451 A; Figure 17 of the instruction manual, page 33 of 16 / 17, CN 121666451 A; Figure 18 of the instruction manual, page 34 of 17 / 17, CN 121666451 A.

Claims

1. A TAL effector nuclease pair, comprising a first TAL effector nuclease monomer and a second TAL effector nuclease monomer, The target sequence of the first TAL effector nuclease monomer is 12 to 20 bases away from the target sequence of the second TAL effector nuclease monomer; The first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have: DNA-binding domains containing RVD that bind to DNA of 8–15 bases, and The DNA cleavage domain of FokI endonuclease; The RVD includes: The first RVD that identifies the bases at mitochondrial disease-induced mutation sites, and The second RVD identifies bases other than the mitochondrial disease-induced mutation site; The first RVD is at least one of NM (adenine-recognizing), WK (guanine-recognizing), and LK (guanine-recognizing). The second RVD recognizes adenine by NI and guanine by NN.

2. The TAL effector nuclease pair according to claim 1, wherein, The first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have a DNA cleavage domain of the FokI endonuclease with different amino acid sequences, forming a heterodimer.

3. The TAL effector nuclease pair according to claim 1, which binds to mutant mitochondrial DNA.

4. The TAL effector nuclease pair according to claim 1, which binds to wild-type mitochondrial DNA.

5. The TAL effector nuclease pair according to claim 1, wherein, The mitochondrial disease-induced mutation is the A3243G mutation.

6. The TAL effector nuclease pair according to claim 5, wherein, The RVD in the first TAL effector nuclease monomer is any one of NN-NN-HD-NI-NN-WK-NN-HD―HD-HD-NN, NN-NN-HD-NI-NN-LK-NN-HD―HD-HD-NN, and NN-NN-HD-NI-NN-NM-NN-HD―HD-HD-NN.

7. The TAL effector nuclease pair according to claim 5, wherein, The RVD in the second TAL effector nuclease monomer is any one of NI-NI-NI-NN-NG-NG-NG-NG―NI-NI-NN-NG, NI-NI-NI-NN-NG-NG-NG―NI-NI-NN, and NN-NG-NI-NI-NI-NN-NG-NG-NG―NI-NI-NN-NG.

8. The TAL effector nuclease pair according to claim 5, wherein, The first TAL effector nuclease monomer is any one of the following amino acid sequences: The amino acid sequence shown in any one of sequence numbers 1 to 3, Amino acid sequences that have more than 90% homology with the amino acid sequences shown in any one of sequence numbers 1 to 3, and An amino acid sequence in which one or more amino acid residues are missing, substituted, or added in any one of the amino acid sequences shown in sequence numbers 1 to 3. The second TAL effector nuclease monomer is any one of the following amino acid sequences: The amino acid sequence represented by any one of sequence numbers 4, 19, and 20 Amino acid sequences that share more than 90% homology with any one of the amino acid sequences shown in sequence number 4, sequence number 19, and sequence number 20, and An amino acid sequence in which one or more amino acids are missing, substituted, or added in any of the amino acid sequences shown in sequence number 4, sequence number 19, or sequence number 20.

9. A nucleic acid composition comprising a first nucleic acid encoding a first TAL effector nuclease monomer and a second nucleic acid encoding a second TAL effector nuclease monomer. The target sequence of the first TAL effector nuclease monomer is 12 to 20 bases away from the target sequence of the second TAL effector nuclease monomer; The first TAL effector nuclease monomer and the second TAL effector nuclease monomer each have: DNA-binding domains containing RVD that bind to DNA of 8–15 bases, and The DNA cleavage domain of FokI endonuclease; The RVD includes: The first RVD that identifies the bases at mitochondrial disease-induced mutation sites, and Second RVD that recognizes bases other than mutation sites induced by mitochondrial diseases; The first RVD is at least one of NM (adenine-recognizing), WK (guanine-recognizing), and LK (guanine-recognizing). The second RVD recognizes adenine by NI and guanine by NN.

10. A carrier comprising the nucleic acid composition of claim 9.

11. A pharmaceutical composition comprising any one of the TAL effector nuclease pairs of claims 1 to 8, the nucleic acid composition of claim 9, or the carrier of claim 10.